Justin Sheehy, MD
Interventional Cardiology · Saint Louis, MONPI 1528407822
Payments from drug & device makers
What this record shows
This record is dominated by grants: $62,500 of the $73,829 with a category attached, or 84.7%. 21 manufacturers reported payments, led by Medtronic at 52.2% of the total. Reporting peaked in 2020 at $52,230 and has fallen 97.2% since, to $1,443 in 2025.
Across 269 payments — averaging $274.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$39K
- Boston Scientific$16K
- Abbott$15K
- Edwards Lifesciences$4K
- Abiomed$236
- Novartis$128
- plus $778 from 15 others
What the payments were for
- Grants$62,50085%
- Travel & lodging$3,1854%
- Food & beverage$7,93311%
- Education$2100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 42 | $38,545 |
| Boston Scientific | 11 | $15,534 |
| Abbott | 17 | $14,809 |
| Edwards Lifesciences | 165 | $3,799 |
| Abiomed | 2 | $236 |
| Novartis | 7 | $128 |
| Acist Medical Systems, Inc. | 1 | $127 |
| Philips North America LLC | 1 | $91 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $88 |
| Shockwave Medical, Inc | 1 | $74 |
| Terumo Medical Corporation | 1 | $69 |
| Heartflow, Inc. | 1 | $57 |
| Amgen | 4 | $56 |
| Merck | 3 | $46 |
| Pfizer | 3 | $41 |
| Asahi Intecc USA, Inc. | 2 | $41 |
| Siemens Medical Solutions USA, Inc. | 1 | $28 |
| Boehringer Ingelheim | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $13 |
| Novo Nordisk | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$73,829 in reported general payments places this provider in the 85th percentile of 182 interventional cardiology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 343 | $313,242 |
| EntrestoSacubitril/Valsartan | 156 | $150,612 |
| JardianceEmpagliflozin | 140 | $121,218 |
| FarxigaDapagliflozin Propanediol | 85 | $75,956 |
| Repatha SureclickEvolocumab | 55 | $53,271 |
| XareltoRivaroxaban | 39 | $34,497 |
| Atorvastatin Calcium | 635 | $8,688 |
| BrilintaTicagrelor | 11 | $6,104 |
| Prasugrel Hcl | 46 | $6,006 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 23 | $5,804 |
| Torsemide | 350 | $5,785 |
| Rosuvastatin Calcium | 443 | $5,464 |
| Ezetimibe | 185 | $3,885 |
| ClopidogrelClopidogrel Bisulfate | 308 | $2,756 |
| Metoprolol Tartrate | 344 | $2,215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $41 | $313,242343 claims |
| NovartisEntresto | $128 | $150,612156 claims |
| Boehringer IngelheimJardiance | $19 | $121,218140 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 182 interventional cardiology providers in Missouri.
Other interventional cardiology in Saint Louis
- John LasalaSaint Louis$936K
- Harvey SerotaSaint Louis$752K
- Jasvindar SinghSaint Louis$696K
- Alan ZajariasSaint Louis$203K
- Anish ThomasSaint Louis$171K
- Gus TheodosSaint Louis$165K
- Prashanth ThakkerSaint Louis$129K
- Marc SintekSaint Louis$119K
- George KichuraSaint Louis$118K
- Gil VardiSaint Louis$106K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.